A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. We evaluate the efficacy of the ora...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Ullrich, Nicole J, Prabhu, Sanjay P, Reddy, Alyssa T, Fisher, Michael J, Packer, Roger, Goldman, Stewart, Robison, Nathan J, Gutmann, David H, Viskochil, David H, Allen, Jeffrey C, Korf, Bruce, Cantor, Alan, Cutter, Gary, Thomas, Coretta, Perentesis, John P, Mizuno, Tomoyuki, Vinks, Alexander A, Manley, Peter E, Chi, Susan N, Kieran, Mark W
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Pediatric Neuro-Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566451/
https://ncbi.nlm.nih.gov/pubmed/32236425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa071
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares